Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-cash Items (2021 - 2025)

Historic Non-cash Items for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $11.8 million.

  • SAB Biotherapeutics' Non-cash Items rose 7101.45% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 7101.45%. This contributed to the annual value of $6.3 million for FY2024, which is 84741.54% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Non-cash Items is $11.8 million, which was up 7101.45% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Non-cash Items ranged from a high of $28.9 million in Q4 2021 and a low of $109891.0 during Q4 2022
  • Its 5-year average for Non-cash Items is $6.9 million, with a median of $5.2 million in 2022.
  • As far as peak fluctuations go, SAB Biotherapeutics' Non-cash Items crashed by 9961.98% in 2022, and later skyrocketed by 84741.54% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Non-cash Items stood at $28.9 million in 2021, then tumbled by 99.62% to $109891.0 in 2022, then soared by 505.12% to $664967.0 in 2023, then surged by 847.42% to $6.3 million in 2024, then surged by 87.3% to $11.8 million in 2025.
  • Its Non-cash Items stands at $11.8 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.7 million for Q1 2025.